Literature DB >> 29581114

Determination of the Dynamically Linked Indices of Fosfomycin for Pseudomonas aeruginosa in the Hollow Fiber Infection Model.

Arnold Louie1, Michael Maynard1, Brandon Duncanson1, Jocelyn Nole1, Michael Vicchiarelli1, G L Drusano2.   

Abstract

Fosfomycin is the only expoxide antimicrobial and is currently under development in the United States as an intravenously administered product. We were interested in identifying the exposure indices most closely linked to its ability to kill bacterial cells and to suppress amplification of less susceptible subpopulations. We employed the hollow fiber infection model for this investigation and studied wild-type strain Pseudomonas aeruginosa PAO1. Because of anticipated rapid resistance emergence, we shortened the study duration to 24 h but sampled the system more intensively. Doses of 12 and 18 g/day and schedules of daily administration, administration every 8 h, and administration by continuous infusion for each daily dose were studied. We measured fosfomycin concentrations (by liquid chromatography-tandem mass spectrometry), the total bacterial burden, and the burden of less susceptible isolates. We applied a mathematical model to all the data simultaneously. There was a rapid emergence of resistance with all doses and schedules. Prior to resistance emergence, an initial kill of 2 to 3 log10(CFU/ml) was observed. The model demonstrated that the area under the concentration-time curve/MIC ratio was linked to total bacterial kill, while the time that the concentration remained above the MIC (or, equivalently, the minimum concentration/MIC ratio) was linked to resistance suppression. These findings were also seen in other investigations with Enterobacteriaceae (in vitro systems) and P. aeruginosa (murine system). We conclude that for serious infections with high bacterial burdens, fosfomycin may be of value as a new therapeutic and may be optimized by administering the agent as a continuous or prolonged infusion or by use of a short dosing interval. For indications such as ventilator-associated bacterial pneumonia, it may be prudent to administer fosfomycin as part of a combination regimen.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Pseudomonas aeruginosa; fosfomycin; hollow fiber infection model; pharmacodynamics

Mesh:

Substances:

Year:  2018        PMID: 29581114      PMCID: PMC5971584          DOI: 10.1128/AAC.02627-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

Review 1.  Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 1.

Authors:  G L Drusano; Arnold Louie; Alasdair MacGowan; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

Review 2.  Suppression of Emergence of Resistance in Pathogenic Bacteria: Keeping Our Powder Dry, Part 2.

Authors:  G L Drusano; William Hope; Alasdair MacGowan; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2015-12-28       Impact factor: 5.191

3.  Phosphonomycin, a new antibiotic produced by strains of streptomyces.

Authors:  D Hendlin; E O Stapley; M Jackson; H Wallick; A K Miller; F J Wolf; T W Miller; L Chaiet; F M Kahan; E L Foltz; H B Woodruff; J M Mata; S Hernandez; S Mochales
Journal:  Science       Date:  1969-10-03       Impact factor: 47.728

4.  Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model.

Authors:  Brian D VanScoy; Jennifer McCauley; Evelyn J Ellis-Grosse; Olanrewaju O Okusanya; Sujata M Bhavnani; Alan Forrest; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2015-06-22       Impact factor: 5.191

5.  Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.

Authors:  F Docobo-Pérez; G L Drusano; A Johnson; J Goodwin; S Whalley; V Ramos-Martín; M Ballestero-Tellez; J M Rodriguez-Martinez; M C Conejo; M van Guilder; J Rodríguez-Baño; A Pascual; W W Hope
Journal:  Antimicrob Agents Chemother       Date:  2015-06-29       Impact factor: 5.191

6.  In Vivo Pharmacokinetics and Pharmacodynamics of ZTI-01 (Fosfomycin for Injection) in the Neutropenic Murine Thigh Infection Model against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.

Authors:  Alexander J Lepak; Miao Zhao; Brian VanScoy; Daniel S Taylor; Evelyn Ellis-Grosse; Paul G Ambrose; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

  6 in total
  10 in total

1.  Activity of fosfomycin and amikacin against fosfomycin-heteroresistant Escherichia coli strains in a hollow-fiber infection model.

Authors:  I Portillo-Calderón; M Ortiz-Padilla; B de Gregorio-Iaria; V Merino-Bohorquez; J Blázquez; J Rodríguez-Baño; J M Rodríguez-Martínez; A Pascual; F Docobo-Pérez
Journal:  Antimicrob Agents Chemother       Date:  2021-03-08       Impact factor: 5.191

2.  Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic In Vitro Model.

Authors:  Iain J Abbott; Elke van Gorp; Aart van der Meijden; Rixt A Wijma; Joseph Meletiadis; Jason A Roberts; Johan W Mouton; Anton Y Peleg
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

3.  Population pharmacokinetics and Monte Carlo simulation for dosage optimization of fosfomycin in the treatment of osteoarticular infections in patients without renal dysfunction.

Authors:  Matteo Rinaldi; Pier Giorgio Cojutti; Eleonora Zamparini; Sara Tedeschi; Nicolò Rossi; Matteo Conti; Maddalena Giannella; Federico Pea; Pierluigi Viale
Journal:  Antimicrob Agents Chemother       Date:  2021-02-22       Impact factor: 5.191

4.  The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection Model.

Authors:  G L Drusano; M N Neely; W M Yamada; Brandon Duncanson; David Brown; Michael Maynard; Michael Vicchiarelli; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

5.  Clinical Pharmacokinetics of Fosfomycin after Continuous Infusion Compared with Intermittent Infusion: a Randomized Crossover Study in Healthy Volunteers.

Authors:  Valentin Al Jalali; Peter Matzneller; Beatrix Wulkersdorfer; Scharon Chou; Soma Bahmany; Birgit C P Koch; Markus Zeitlinger
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

Review 6.  Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans.

Authors:  Jürgen B Bulitta; William W Hope; Ann E Eakin; Tina Guina; Vincent H Tam; Arnold Louie; George L Drusano; Jennifer L Hoover
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

7.  Development and Validation of an HPLC-UV Method for Quantitation of Linezolid: Application to Resistance Study Using in vitro PK/PD Model.

Authors:  Guang Yang; Yisong Yan; Jun Mao; Huiping Liu; Mingtao Chen; Na Zhang; Yaowen Li; Jiangjun Gu; Xiaohui Huang
Journal:  Infect Drug Resist       Date:  2021-12-01       Impact factor: 4.003

8.  Polymyxin B Pharmacodynamics in the Hollow-Fiber Infection Model: What You See May Not Be What You Get.

Authors:  Michael Maynard; G L Drusano; Michael Vicchiarelli; Weiguo Liu; Jenny Myrick; Jocelyn Nole; Brandon Duncanson; David Brown; Arnold Louie
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191

Review 9.  Treatment options for K. pneumoniae, P. aeruginosa and A. baumannii co-resistant to carbapenems, aminoglycosides, polymyxins and tigecycline: an approach based on the mechanisms of resistance to carbapenems.

Authors:  Stamatis Karakonstantis; Evangelos I Kritsotakis; Achilleas Gikas
Journal:  Infection       Date:  2020-09-01       Impact factor: 3.553

Review 10.  Predicting Antimicrobial Activity at the Target Site: Pharmacokinetic/Pharmacodynamic Indices versus Time-Kill Approaches.

Authors:  Wisse van Os; Markus Zeitlinger
Journal:  Antibiotics (Basel)       Date:  2021-12-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.